Sildenafil Pharmacokinetics: Bioavailability, Food Effects, Dose Response, and Practical Timing

Sildenafil transformed the treatment of erectile dysfunction because it combined oral administration with predictable clinical activity. Yet the tablet does not work according to a stopwatch. Its effect depends on how quickly the drug is absorbed, how much reaches the circulation, how rapidly it is metabolised, what has been eaten, and whether the patient has conditions or medications that alter drug clearance.

A foundational clinical investigation by Nichols, Muirhead, and Harness examined three central questions: how much orally administered sildenafil reaches the bloodstream, how a high-fat meal changes its pharmacokinetic profile, and whether increasing the dose produces a proportional increase in systemic exposure. The work consisted of three open-label, randomised crossover studies in healthy male volunteers and remains one of the key sources behind the familiar instructions to take sildenafil approximately one hour before sexual activity and to expect a slower onset after a substantial meal. (PMC)

The results were pharmacologically elegant but clinically practical. Sildenafil was absorbed rapidly, had an average absolute oral bioavailability of 41%, reached its highest concentration at approximately one hour in fasting subjects, and had a terminal half-life of roughly four hours. A high-fat meal delayed absorption and reduced the peak concentration, while increasing doses from 25 to 200 mg produced slightly greater than proportional increases in exposure. These findings explain both the flexibility and the limitations of sildenafil therapy: timing matters, food may matter, and simply adding more milligrams is not a sophisticated solution to every disappointing response.

Why Sildenafil Pharmacokinetics Matters in Real Life

Sildenafil is a phosphodiesterase type 5 inhibitor. During sexual stimulation, nitric oxide released in penile tissue promotes the production of cyclic guanosine monophosphate, or cGMP. This intracellular messenger relaxes smooth muscle and supports increased blood flow. PDE5 normally breaks down cGMP; sildenafil inhibits that enzyme and allows the natural erectile response to persist more effectively. It does not create sexual desire, initiate an erection without stimulation, or replace the vascular and neurological processes required for normal sexual function.

Pharmacokinetics describes what the body does to a medicine. Four measurements are especially useful. The maximum plasma concentration, or Cmax, describes the highest measured level of the drug. Tmax is the time required to reach that peak. The area under the concentration-time curve, or AUC, represents total systemic exposure. The elimination half-life indicates how long it takes for the plasma concentration to fall by approximately half during the terminal elimination phase.

These measurements are related but not interchangeable. A meal may reduce Cmax and delay Tmax without dramatically changing AUC. In practical terms, the medicine may enter the bloodstream more slowly and produce a less pronounced early peak, while the total amount reaching the circulation remains reasonably similar. This distinction explains why sildenafil taken after dinner may still work, yet begin working later than expected.

Systemic exposure is also not identical to erectile response. Plasma concentration contributes to pharmacological activity, but the clinical result depends on sexual stimulation, vascular function, neurological integrity, the cause and severity of erectile dysfunction, psychological context, and correct use of the medication. Pharmacokinetics sets the stage; it does not perform the entire play.

The original investigation was therefore important because it connected measurable drug concentrations with a practical treatment schedule. Its findings supported an oral therapy that could be taken when needed, absorbed within a useful period, remain active long enough for reasonable flexibility, and then be cleared without extensive accumulation. The stomach, liver, and circulation were doing more than processing a tablet; they were defining how the treatment would be used.

How the Foundational Sildenafil Study Was Designed

The publication combined three separate crossover studies. In a crossover design, each participant receives more than one study treatment at different times, separated by washout periods. This allows comparisons within the same individual and reduces some of the variability caused by differences in body size, metabolism, absorption, and other personal characteristics.

The absolute-bioavailability study included 12 healthy men who received sildenafil as both a 50 mg oral dose and a 50 mg intravenous infusion. Intravenous administration places the drug directly into the systemic circulation and is therefore treated as 100% available. Comparing dose-adjusted AUC values after oral and intravenous administration allowed the researchers to calculate the proportion of an oral dose that survived gastrointestinal absorption and first-pass metabolism.

The food-effect study included 34 participants. Each received a single oral 100 mg dose under fasting conditions and after a high-fat breakfast. The standardised meal contained approximately 68 g of fat and provided more than 4,000 kilojoules. Blood sampling allowed the investigators to compare sildenafil and its active primary circulating metabolite, then known as UK-103,320 and now commonly called N-desmethyl sildenafil.

The dose-proportionality study evaluated single doses of 25, 50, 100, and 200 mg in 32 healthy men. Each participant received the four doses in a randomised sequence, with washout periods of at least seven days. The investigators measured whether Cmax and AUC increased in direct proportion to dose and whether Tmax or the elimination rate changed meaningfully as the dose increased.

All three studies were open-label rather than blinded. Participants were healthy men aged 18 to 45 years, generally without significant medical conditions or regular medications. This created a controlled setting for measuring pharmacokinetics, although it also limited direct generalisation to older patients and people with cardiovascular disease, diabetes, hepatic impairment, renal impairment, or multiple concurrent treatments. The studies were funded by Pfizer Central Research, which employed the authors. (PMC)

From Tablet to Bloodstream: Absorption, Bioavailability, and Elimination

After the fasting oral dose, sildenafil entered the circulation rapidly. In the absolute-bioavailability study, peak concentrations occurred between 30 minutes and 2.5 hours, with an average Tmax of approximately 1.46 hours. In the dose-ranging study, average Tmax values were close to one hour across all four doses. Current European product information similarly states that maximum plasma concentrations are usually reached within 30 to 120 minutes, with a median of 60 minutes in the fasting state. (European Medicines Agency (EMA))

The calculated absolute oral bioavailability was 41%, with a 90% confidence interval of approximately 36% to 47%. Bioavailability of 41% does not mean that the tablet is “only 41% effective.” It means that about 41% of the administered sildenafil dose reaches the systemic circulation as unchanged parent drug when oral and intravenous exposure are compared. The remainder is affected primarily by metabolism in the intestinal wall and liver before it can circulate throughout the body.

This first-pass metabolism is not an accidental loss. It is a normal part of oral drug handling. Sildenafil is metabolised mainly by CYP3A4 and, to a lesser extent, CYP2C9. N-demethylation produces its major circulating active metabolite. That metabolite has a PDE5 selectivity profile similar to sildenafil and about half of the parent compound’s in-vitro potency. Its plasma concentration is approximately 40% to 45% of the parent-drug concentration, meaning it contributes materially, although secondarily, to the overall pharmacological effect. (Access Data)

The study also reported a mean steady-state volume of distribution of approximately 105 litres. Because this is substantially greater than total body-water volume, sildenafil is not confined to the blood. It distributes into tissues and is highly protein bound. Current product information states that sildenafil and N-desmethyl sildenafil are approximately 96% bound to plasma proteins, with binding largely independent of total concentration.

Total body clearance after intravenous administration was approximately 41 litres per hour. This relatively substantial clearance is consistent with the liver being the principal site of elimination. Following metabolism, sildenafil-related material is excreted mainly in faeces, accounting for approximately 80% of the oral dose, and to a lesser extent in urine, accounting for about 13%. The parent drug is therefore not primarily removed unchanged by the kidneys.

The terminal half-life was approximately four hours. Oral and intravenous administration produced similar terminal half-lives, indicating that the route of administration changed the amount and rate of drug reaching the circulation but did not meaningfully change the final elimination process. In the dose-ranging study, mean half-life values ranged from approximately 2.6 hours after 25 mg to 3.8 hours after 200 mg. The authors attributed much of this apparent increase to the terminal phase being easier to measure at higher plasma concentrations rather than to a clinically important dose-dependent change in elimination.

Half-life should not be interpreted as an exact duration of erectile benefit. Drug concentration declines gradually rather than switching off at four hours. Some activity may remain after one half-life, although responsiveness generally becomes less predictable as concentrations fall. The familiar recommendation to take sildenafil approximately one hour before sexual activity reflects average absorption, while the accepted dosing window allows for considerable individual variation. Current product information permits administration approximately 30 minutes to four hours before sexual activity, with no more than one dose per day. (Access Data)

The Food Effect: Why a Heavy Meal Can Delay the Result

The food-effect study produced one of the most clinically recognisable findings in sildenafil pharmacology. When participants took 100 mg after a high-fat meal, average Tmax increased from 0.95 hours to 2.04 hours. In other words, the peak was delayed by approximately 1.1 hours. Cmax fell from 514 ng/mL in the fasting state to 364 ng/mL in the fed state, representing an average reduction of 29%.

Total exposure changed much less dramatically. Mean AUC fell from 1,670 to 1,489 ng·h/mL, an average reduction of approximately 11%. The study authors considered this decrease unlikely to be clinically significant. The active metabolite showed a similar pattern: food delayed its appearance, lowered its peak concentration, and modestly reduced total exposure. (Access Data)

These results suggest that food primarily changes the speed of sildenafil absorption rather than preventing absorption altogether. A high-fat meal delays gastric emptying, keeping the tablet and dissolved drug in the stomach for longer before they reach the small intestine, where absorption is more efficient. The outcome is a flatter and later concentration curve. The dose has not disappeared; it is simply arriving late to an appointment the patient may have scheduled rather precisely.

This distinction is important when counselling patients who say that sildenafil “did not work.” A tablet taken immediately after a large meal may not have reached an adequate concentration by the time sexual activity was attempted. Taking another tablet too soon is not the correct response and may create excessive exposure later, when both doses are being absorbed or remain active.

For the conventional film-coated tablet, sildenafil may be taken with or without food, but a heavy or high-fat meal can delay its onset. A person seeking the most predictable timing will generally obtain a faster rise in plasma concentration by taking it on an empty stomach or after a light meal. Current EMA information continues to report a mean food-related delay in Tmax of 60 minutes and a 29% reduction in Cmax for film-coated tablets. (European Medicines Agency (EMA))

Food effects may differ between formulations. Orodispersible tablets and films are convenient, but dissolving in the mouth does not necessarily bypass gastrointestinal absorption or hepatic first-pass metabolism. Current European information reports an even more pronounced delay for the 50 mg orodispersible tablet when taken after a high-fat meal. Formulation-specific instructions should therefore be followed rather than assuming that every product bearing the name sildenafil behaves identically. (European Medicines Agency (EMA))

Dose Proportionality and the Myth That More Must Work Faster

In the dose-ranging study, mean Cmax values increased from 127 ng/mL after 25 mg to 271 ng/mL after 50 mg, 560 ng/mL after 100 mg, and 1,150 ng/mL after 200 mg. Mean AUC values increased from 361 to 738, 1,685, and 3,755 ng·h/mL across the same doses. At first glance, this looks close to proportional: twice the dose produced approximately twice the peak concentration and total exposure.

More detailed statistical analysis found a slight deviation from perfect proportionality across the complete 25-200 mg range. A twofold increase in dose was predicted to produce a 2.08-fold increase in Cmax and a 2.23-fold increase in AUC. Exposure therefore increased slightly more than dose, especially when the lowest and highest doses were compared.

The investigators regarded this non-proportionality as too small to be clinically important. Within the currently recommended 25-100 mg range, regulatory information describes sildenafil pharmacokinetics as dose proportional. This apparent difference is not contradictory. The original study assessed a wider range extending to 200 mg, while product information focuses on the approved dosage range.

Increasing the dose did not meaningfully accelerate absorption. Average Tmax remained close to one hour at 25, 50, 100, and 200 mg. A 100 mg tablet therefore does not reliably start working twice as quickly as a 50 mg tablet. It mainly creates greater systemic exposure. More milligrams are not a stopwatch.

Higher exposure may improve response in some patients who do not obtain adequate benefit from a lower dose, but it can also increase adverse effects. In the study, the incidence of adverse events rose with dose. Reported treatment-related events included headache, nausea, dizziness, vasodilatation, limb pain, eye discomfort, and abnormal vision. They were generally mild to moderate and transient, but visual symptoms were particularly associated with the 200 mg dose.

The approved maximum dose for erectile dysfunction remains 100 mg once per day. Current European product information notes that doses above 100 mg do not increase efficacy but may increase the frequency or severity of adverse effects. Dose adjustment should therefore be based on response, tolerability, medical history, and interacting treatments rather than frustration after one poorly timed attempt. (European Medicines Agency (EMA))

Translating the Pharmacokinetics into Better Clinical Use

For many adults with erectile dysfunction, treatment begins with 50 mg taken approximately one hour before anticipated sexual activity. Depending on efficacy and tolerability, the dose may be reduced to 25 mg or increased to 100 mg. Sildenafil requires sexual stimulation and should not be taken more than once daily. These are general product recommendations, not a substitute for an individual medical assessment. (Access Data)

A fasting interval is not an absolute requirement for the film-coated tablet. However, patients who want the most predictable onset should understand that a large, fatty meal can shift the concentration peak by about an hour and sometimes longer. Taking the tablet after a lighter meal, allowing more time before sexual activity, or discussing timing with a clinician is usually more rational than immediately increasing the dose.

Individual exposure may differ substantially from the averages measured in young, healthy volunteers. Older adults have reduced sildenafil clearance and higher plasma concentrations. Severe renal impairment can approximately double Cmax and AUC, while mild to moderate hepatic cirrhosis has been associated with an AUC increase of about 84% and a Cmax increase of roughly 47%. A 25 mg starting dose may therefore be considered in older patients and in those with severe renal or hepatic impairment. (PubMed)

Drug interactions can change exposure even more dramatically. Because CYP3A4 is the major metabolic pathway, strong inhibitors can slow sildenafil clearance and raise plasma concentrations. Ritonavir produces a particularly large interaction, while ketoconazole, itraconazole, erythromycin, clarithromycin, and some other CYP3A4 inhibitors may also increase exposure. CYP3A4 inducers may have the opposite effect and reduce sildenafil concentrations. (PubMed)

Pharmacokinetic interactions are not the only safety concern. Sildenafil must not be combined with nitrates or nitric oxide donors because the combination can produce a dangerous fall in blood pressure. Caution is also required with alpha-blockers and in patients whose cardiovascular condition makes sexual activity inadvisable. A medication history is not bureaucratic decoration here; it is part of the treatment.

The original healthy-volunteer studies found no serious treatment-related adverse events, clinically important electrocardiographic changes, or consistent heart-rate effects. Most adverse events resolved spontaneously. Nevertheless, the trials were small and not designed to detect rare complications. Their reassuring tolerability findings should be interpreted as evidence about short-term single-dose use under controlled conditions, not as proof that every patient can safely take sildenafil.

A patient who obtains an inadequate response should first review administration technique. Was the medication taken early enough? Was it taken after a heavy meal? Was adequate sexual stimulation present? Was the product obtained from a legitimate pharmacy? Were several properly conducted attempts made? Only after these questions are addressed should dose escalation or an alternative treatment be considered with a healthcare professional.

What the Study Established—and What It Could Not Establish

The investigation had several strengths. Its crossover designs reduced between-person variability, intravenous administration allowed a direct calculation of absolute bioavailability, the food challenge was standardised, and dose proportionality was evaluated across a broad range. The researchers also measured the active metabolite and used frequent blood sampling with validated analytical methods.

Its limitations are equally important. The samples were small, the studies were open-label, and all participants were young or middle-aged healthy men. People with erectile dysfunction are often older and may have diabetes, cardiovascular disease, kidney impairment, liver disease, obesity, or multiple medications. Those factors can change both sildenafil exposure and clinical response.

The work evaluated single doses rather than long-term treatment. It was designed primarily to measure concentrations, not to determine the probability of successful intercourse at each time point. The 200 mg dose was useful for defining pharmacokinetic behaviour, but it is above the approved maximum dose for erectile dysfunction and should not be interpreted as a routine treatment option.

The research was also sponsored and conducted by the manufacturer. Industry sponsorship does not invalidate the results, particularly when the design, methods, and numerical data are openly reported, but it remains relevant when considering potential bias. Independent replication and continued pharmacovigilance are always valuable.

Despite these limitations, the principal findings have proved durable. Current regulatory information still describes approximately 41% oral bioavailability, a fasting Tmax of 30-120 minutes, a four-hour terminal half-life, a 29% reduction in Cmax after a high-fat meal, metabolism mainly through CYP3A4, and a 105-litre apparent volume of distribution. The study did not merely produce an attractive concentration curve; it established the pharmacokinetic logic behind the way sildenafil is prescribed today.

Frequently Asked Questions

Does 41% bioavailability mean that most of the sildenafil tablet is wasted?
No. It means that approximately 41% of the oral dose reaches the systemic circulation as unchanged sildenafil. The rest is affected mainly by intestinal and hepatic first-pass metabolism. The approved doses were developed with this bioavailability in mind, so the number does not indicate poor effectiveness.

Should sildenafil always be taken on an empty stomach?
The conventional film-coated tablet may be taken with or without food. However, a high-fat meal can delay Tmax by approximately one hour and reduce Cmax by about 29%. Taking it without a heavy meal generally produces a faster and more predictable onset. (Access Data)

Will 100 mg begin working faster than 50 mg?
Not necessarily. In the dose-ranging study, Tmax remained close to one hour across doses from 25 to 200 mg. A higher dose increases exposure, but it does not reliably accelerate absorption. The dose should be increased only when clinically appropriate and should not exceed 100 mg once daily.

Why might the same dose work differently on different occasions?
Meal composition, timing, sexual stimulation, alcohol consumption, psychological stress, underlying vascular function, interacting medicines, and natural variation in absorption can all influence the experience. A single disappointing attempt does not automatically prove treatment failure.

How long does sildenafil remain in the body?
Its terminal half-life is approximately three to five hours. Concentrations decline progressively over several half-lives, although the clinically useful period is not identical in every patient. The medicine should still be taken no more than once per day.

Sources

• Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. British Journal of Clinical Pharmacology. 2002;53(Suppl 1):5S-12S. (PubMed)
• Pfizer. VIAGRA (sildenafil citrate) Full Prescribing Information.
• European Medicines Agency. VIAGRA: Summary of Product Characteristics and Product Information. (European Medicines Agency (EMA))
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology. 2001;51:239-248. (PubMed)
• Muirhead GJ et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology. 2000. (PubMed)
• Muirhead GJ et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. British Journal of Clinical Pharmacology. 2002. (PubMed)